Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers

  • S. Y. Park
  • , J. S. Lee
  • , J. S. Son
  • , J. H. Ko
  • , K. R. Peck
  • , Y. Jung
  • , H. J. Woo
  • , Y. S. Joo
  • , J. S. Eom
  • , H. Shi

Research output: Contribution to journalArticlepeer-review

68 Scopus citations

Abstract

An effective post-exposure prophylaxis (PEP) strategy may limit the spread of infection. However, there is no consensus regarding PEP for Middle East respiratory syndrome coronavirus (MERS-CoV) infection. This study assessed the efficacy of ribavirin and lopinavir/ritonavir as PEP for healthcare workers (HCWs) exposed to patients with severe MERS-CoV pre-isolation pneumonia. The safety of the PEP regimen was assessed. HCWs with high-risk exposure to MERS-CoV pre-isolation pneumonia were retrospectively enrolled. HCWs who received PEP therapy were classified into the PEP group. PEP therapy was associated with a 40% decrease in the risk of infection. There were no severe adverse events during PEP therapy.

Original languageEnglish
Pages (from-to)42-46
Number of pages5
JournalJournal of Hospital Infection
Volume101
Issue number1
DOIs
StatePublished - Jan 2019

Keywords

  • Healthcare worker
  • High-risk exposure
  • Middle East respiratory syndrome coronavirus
  • Outbreak
  • Post-exposure prophylaxis
  • Pre-isolation pneumonia

Fingerprint

Dive into the research topics of 'Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers'. Together they form a unique fingerprint.

Cite this